Drug or treatment

Secukinumab clinical trials

• 12Clinical trials
• 24Countries

Newest trials

All recruiting trials (12)

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• Long-term real-world tracking of secukinumab treatment for moderate to severe hidradenitis suppurativa in Italy

  This project will see how secukinumab works and is used in adults with moderate to severe hidradenitis suppurativa in Italy.

  Recruiting at 16 sites Novartis · Ancona, AN and 15 other locations · NCT07543419

• Secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa

  This trial tests two dosing regimens of secukinumab to see if they can help Chinese adults with moderate to severe hidradenitis suppurativa.

  Recruiting at 10 sites Phase 4 Novartis · Guangzhou, Guangdong and 9 other locations · NCT07489573

• Secukinumab outcomes in Canadians with hidradenitis suppurativa

  It will see how well secukinumab works and how safe it is for adults in Canada with moderate-to-severe hidradenitis suppurativa who were newly prescribed it in routine care.

  Recruiting at 15 sites Novartis · Calgary, Alberta and 14 other locations · NCT07282015

• Post-marketing surveillance of Cosentyx (secukinumab) for hidradenitis suppurativa, pediatric plaque psoriasis, and juvenile idiopathic arthritis in Korea

  This study will see how Cosentyx (secukinumab) works and is tolerated in people in Korea with moderate-to-severe hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis who are being treated in routine care.

  Recruiting Novartis · Seoul, Seoul · NCT07243782

• Secukinumab for moderate-to-severe hidradenitis suppurativa

  This study tests whether secukinumab helps adults with moderate-to-severe hidradenitis suppurativa who have not improved with antibiotics, isotretinoin, or TNF inhibitors.

  Recruiting Peking Union Medical College · Beijing, Beijing Municipality · NCT07109765

• Evaluating secukinumab's effectiveness with surgery for hidradenitis suppurativa

  This study is testing if using secukinumab along with surgery can help people with moderate to severe hidradenitis suppurativa feel better and have fewer problems after surgery.

  Recruiting Peking Union Medical College · Nanjing, Jiangsu · NCT06926192

• Evaluating secukinumab effectiveness in Korean patients with ankylosing spondylitis

  This study is testing how well secukinumab works for Korean patients with ankylosing spondylitis who haven't tried other treatments before.

  Recruiting at 3 sites Novartis · Jinju, Gyeongsangnam-do and 2 other locations · NCT06905288

• Short-term treatment satisfaction with Cosentyx for hidradenitis suppurativa in Saudi Arabia

  This will see if adults in Saudi Arabia with moderate-to-severe hidradenitis suppurativa who start Cosentyx are satisfied with its convenience, safety, and effectiveness after 24 weeks.

  Recruiting at 4 sites Novartis · Riyadh, SAU and 3 other locations · NCT06785779

• Evaluating the safety and effectiveness of intravenous secukinumab in children with juvenile psoriatic arthritis.

  This study is testing if an intravenous medication called secukinumab is safe and effective for children with juvenile psoriatic arthritis.

  Recruiting at 11 sites Phase 1 Novartis · Loma Linda, California and 10 other locations · NCT06751238

• Secukinumab 300 mg for active ankylosing spondylitis in Chinese adults

  This study tests whether secukinumab 300 mg can help Chinese adults with active ankylosing spondylitis who did not respond to at least two NSAIDs and who have not received biologic treatments.

  Recruiting at 3 sites Phase 4 Tongji Hospital · Wuhan, Hubei and 2 other locations · NCT05303285

• Long-term treatment with secukinumab for patients who completed a previous trial

  This study is testing if long-term treatment with secukinumab can keep helping people with autoimmune and inflammatory conditions who did well in a previous trial.

  Recruiting at 17 sites Phase 4 Novartis · Fullerton, California and 172 other locations · NCT04638647

Quick answers

How many clinical trials of Secukinumab are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in China (5 trials), South Korea (3 trials), United States (2 trials), Spain (2 trials), Italy (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 4: 3, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →